Cytos Biotechnology AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cytos Biotechnology AG
Stock Watch: Funding Biotech In A Hostile Environment
When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.
Stock Watch: Beware The Halo Effect Of Biopharma Leaders
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
- Other Names / Subsidiaries
- Kuros Biosciences Ltd., Kuros Biosurgery Holding AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.